Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose-Escalation Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Next Previous
Trial Profile

An Open-Label, Dose-Escalation Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STI 6129 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Sponsors Sorrento Therapeutics

Most Recent Events

  • 26 Apr 2023 Planned initiation date changed from 1 Mar 2023 to 1 Sep 2023.
  • 26 Apr 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 25 Jan 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top